 Extended-release dihydrocodeine is again in current use in Austria for this reason.Research into the usefulness of piritramide, extended-release hydromorphone (including polymer implants lasting up to 90 days), dihydroetorphine and other drugs for ORT is at various stages in a number of countries.The driving principle behind ORT is the program's capacity to facilitate a resumption of stability in the user's life, while they experience reduced symptoms of withdrawal symptoms and less intense drug cravings; however, a strong euphoric effect is not experienced as a result of the treatment drug.